SCHEMBL9956677

SCHEMBL9956677

CN(C(=O)Cl)c1ccc(C#N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.49
CHRNB2 P17787 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA4 P43681 1/20 0.49
CA2 P00918 3/20 0.47
CA1 P00915 2/20 0.47
KMT2A Q03164 1/20 0.46
GPBAR1 Q8TDU6 1/20 0.43
PDK2 Q15119 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CYP2A6 P11509 1/20 0.40
MLNR O43193 1/20 0.40
CA12 O43570 1/20 0.40
CA3 P07451 1/20 0.40
CA6 P23280 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7873808 0.82 PGR (0.61) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL5317092 0.81 CHRNB2 (0.49) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL30204212 0.78 ROCK2 (0.48) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6170106 0.78 KMT2A (0.54) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL2578635 0.78 CHRNB2 (0.47) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL10194676 0.77 CCNK (0.47) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL22312043 0.77 KMT2A (0.52) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL7241629 0.77 CHRNB2 (0.46) PGRCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL8986913 0.75 ALDH1A1 (0.48) CHRNB2CHRNB4CHRNA3CHRNA4CA2
SCHEMBL11616779 0.75 ALDH1A1 (0.50) KMT2AGPBAR1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2018109496-A2 UNNATURAL AMINO ACIDS THE UNIVERSITY OF BRISTOL (GB) 2018-06-21 WO disclosed
EP-2655323-B1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LTD (IE) 2017-12-20 EP disclosed
US-20170217910-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2017-08-03 US disclosed
US-9708286-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2017-07-18 US disclosed
CN-104529827-B Ingenol-3-acylate III and ingenol-3-carbamate 利奥实验室有限公司 2016-08-24 CN disclosed
CN-103402977-B Ingenol-3-acylate III and ingenol-3-carbamate LEO PHARMA A/S (IE) 2016-01-20 CN disclosed
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2015-10-15 US disclosed
US-9102687-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2015-08-11 US disclosed
CN-104529827-A Ingenol-3-acylates III and ingenol-3-carbamates LEO PHARMA AS 2015-04-22 CN disclosed
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2014-10-09 US disclosed
EP-2655323-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2013-10-30 EP disclosed
WO-2012083953-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO PHARMA A/S (DK) 2012-06-28 WO disclosed
US-4033972-A RODENTICIDES ROHM AND HAAS COMPANY (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217910-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG PGR 1544/4885CHRNB2 1809/4885CHRNB4 2098/4885
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG PGR 1544/4885CHRNB2 1809/4885CHRNB4 2098/4885
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG PGR 1544/4885CHRNB2 1809/4885CHRNB4 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.